交银国际每日晨报-20260326

Group 1: WuXi Biologics (2269 HK) - Significant improvement in profit margins expected in 2025, driven by new technologies and CMO [1] - Revenue for 2025 projected at RMB 21.8 billion, a 17% year-on-year increase, with gross margin rising by 5.0 percentage points to 46.0% [1] - Free cash flow expected to grow over 70% to RMB 2.3 billion, with capital expenditures around RMB 7.1 billion [1][2] - Target price raised to HKD 35.80, maintaining a neutral rating [2] Group 2: Gensun Pharmaceuticals (2595 HK) - Revenue for 2025 expected to reach RMB 130 million, a 24% year-on-year increase, with adjusted losses narrowing by 9% to RMB 227 million [3] - Cash reserves at year-end projected to exceed RMB 2 billion, supporting R&D and operations for the next 2-3 years [3] - Anticipated significant sales growth in 2026 following the inclusion of Fluorouracil in the medical insurance directory [3] Group 3: Hesai Technology (2525 HK) - Revenue for Q4 2025 reached RMB 1 billion, a 39% year-on-year increase, with a shipment volume of 631,000 units, up 184.2% [9] - Management raised 2026 shipment guidance to 3-3.5 million units, previously set at 2-3 million [9] - 2025 GAAP net profit expected at RMB 440 million, with a non-GAAP net profit of RMB 550 million [9][10] Group 4: Xiaomi Group (1810 HK) - Q4 2025 total revenue increased by 7% year-on-year to RMB 116.9 billion, with a gross margin of 20.8% [12] - Adjusted net profit decreased by 24% to RMB 6.35 billion, facing storage cost pressures [12][13] - Continued investment in AI expected to reach RMB 16 billion in 2026, with a cumulative investment of RMB 60 billion over three years [13] Group 5: ZhongAn Online (6060 HK) - Net profit for 2025 expected to increase by over 80% to RMB 1.102 billion, with a 198.3% increase when excluding one-time impairment losses [14][15] - Health insurance premium income projected to grow by 20% annually over the next three years [15] - Target price maintained at HKD 23, corresponding to a 1.40x 2026 target P/B ratio [16] Group 6: Henderson Land Development (12 HK) - Revenue for 2025 increased by 1.9% to HKD 25.74 billion, with net profit declining by approximately 10.2% to HKD 5.65 billion [17] - Contract sales in Hong Kong expected to reach HKD 19.271 billion, a 71% year-on-year increase [17] - Target price maintained at HKD 32.68, reflecting a significant discount to net asset value [18]